In a preclinical renal cell carcinoma mouse model, Rayman and colleagues observed that depleting MDSCs with TKI, sunitinib together with checkpoint blockade by anti-PD1 antibody co-treatment resulted in significantly more CD8+ T cells in the tumor (Rayman et al., 2015). This evidence concerns the gene PDCD1 and neoplasm.